Published Online
on January 19, 2004

A more recent version of this article appeared on January 27, 2004

This Article Full Text (PDF) All Versions of this Article: 109/3/340    most recent 01.CIR.0000109488.62415.01v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Waksman, R. Articles by Lindsay, J. Search for Related Content PubMed PubMed Citation Articles by Waksman, R. Articles by Lindsay, J. Related Collections Restenosis Catheter-based coronary interventions: stents

Submitted on March 19, 2003
Revised on October 10, 2003
Accepted on October 13, 2003

Five-Year Follow-Up After Intracoronary Gamma Radiation Therapy for In-Stent Restenosis

Ron Waksman MD^*, Andrew E. Ajani MD, R. Lawrence White MD, Rosanna Chan MD, Bill Bass PhD, Augusto D. Pichard MD, Lowell F. Satler MD, Kenneth M. Kent MD, Rebecca Torguson BS, Regina Deible RN, Ellen Pinnow MS, and Joseph Lindsay MD

From Washington Hospital Center and Washington Cancer Institute at the Washington Hospital Center, Washington, DC.

^* To whom correspondence should be addressed. E-mail: ron.waksman{at}medstar.net.

Background--The Washington Radiation for In-Stent Restenosis Trial is a double-blinded randomized study evaluating the effects of intracoronary radiation therapy (IRT) in patients with in-stent restenosis (ISR).

Methods and Results--One hundred thirty patients with ISR (100 native coronary and 30 vein grafts) underwent percutaneous transluminal coronary angioplasty, laser ablation, rotational atherectomy, or additional stenting (36% of lesions). Patients were randomized to either 192-Iridium IRT or placebo, with a prescribed dose of 15 Gy to a 2-mm radial distance from the center of the source. Angiographic restenosis (27% versus 56%, P=0.002) and target vessel revascularization (26% versus 68%, P<0.001) were reduced at 6 months in patients treated with IRT. Between 6 and 60 months, patients treated with IRT compared with placebo had more target lesion revascularization (IRT, 21.6% versus placebo, 4.7%; P=0.04) and target vessel revascularization (IRT, 21.5% versus placebo, 6.1%; P=0.03). At 5 years, the major adverse cardiac event rate was significantly reduced with IRT (46.2% versus 69.2%, P=0.008).

Conclusions--In the Washington Radiation for In-Stent Restenosis Trial, patients with ISR treated with IRT using 192-Iridium had a reduction in the need for repeat target lesion and vessel revascularization at 6 months and 5 years.

Key words: restenosis • angioplasty • revascularization • radioisotopes

This article has been cited by other articles:

				S. Kufner, J. Hausleiter, G. Ndrepepa, S. Schulz, O. Bruskina, R. A. Byrne, M. Fusaro, A. Kastrati, A. Schomig, J. Mehilli, et al. Long-Term Risk of Adverse Outcomes and New Malignancies in Patients Treated With Oral Sirolimus for Prevention of Restenosis J. Am. Coll. Cardiol. Intv., November 1, 2009; 2(11): 1142 - 1148. [Abstract] [Full Text] [PDF]

				G. Weisz, M. B. Leon, D. R. Holmes Jr, D. J. Kereiakes, J. J. Popma, P. S. Teirstein, S. A. Cohen, H. Wang, D. E. Cutlip, and J. W. Moses Five-year follow-up after sirolimus-eluting stent implantation results of the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) Trial. J. Am. Coll. Cardiol., April 28, 2009; 53(17): 1488 - 1497. [Abstract] [Full Text] [PDF]

				D. J. Fiorella, E. I. Levy, A. S. Turk, F. C. Albuquerque, G. L. Pride Jr, H. H. Woo, B. G. Welch, D. B. Niemann, P. D. Purdy, B. Aagaard-Kienitz, et al. Target Lesion Revascularization After Wingspan: Assessment of Safety and Durability Stroke, January 1, 2009; 40(1): 106 - 110. [Abstract] [Full Text] [PDF]

				F. Crea, P. G. Camici, R. De Caterina, and G. A. Lanza CHAPTER 17 Chronic Ischaemic Heart Disease ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter. [Abstract] [Full Text] [PDF]

				F. Alfonso, M.-J. Perez-Vizcayno, R. Hernandez, A. Bethencourt, V. Marti, J. R. Lopez-Minguez, J. Angel, A. Iniguez, C. Moris, A. Cequier, et al. Long-Term Clinical Benefit of Sirolimus-Eluting Stents in Patients With In-Stent Restenosis: Results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) Study J. Am. Coll. Cardiol., November 11, 2008; 52(20): 1621 - 1627. [Abstract] [Full Text] [PDF]

				D. R. Holmes Jr, P. S. Teirstein, L. Satler, M. H. Sketch Jr, J. J. Popma, L. Mauri, H. Wang, P. A. Schleckser, S. A. Cohen, and SISR Investigators 3-Year Follow-Up of the SISR (Sirolimus-Eluting Stents Versus Vascular Brachytherapy for In-Stent Restenosis) Trial J. Am. Coll. Cardiol. Intv., August 1, 2008; 1(4): 439 - 448. [Abstract] [Full Text] [PDF]

				J. M. Wilson and J. T. Willerson Myocardial Revascularization with Percutaneous Devices Card. Surg. Adult, January 1, 2008; 3(2008): 573 - 598. [Full Text]

				E. Grube, K. D. Dawkins, G. Guagliumi, A. P. Banning, K. Zmudka, A. Colombo, L. Thuesen, K. Hauptman, J. Marco, W. Wijns, et al. TAXUS VI 2-year follow-up: randomized comparison of polymer-based paclitaxel-eluting with bare metal stents for treatment of long, complex lesions Eur. Heart J., November 1, 2007; 28(21): 2578 - 2582. [Abstract] [Full Text] [PDF]

				M. Awata, J.-i. Kotani, M. Uematsu, T. Morozumi, T. Watanabe, T. Onishi, O. Iida, F. Sera, S. Nanto, M. Hori, et al. Serial Angioscopic Evidence of Incomplete Neointimal Coverage After Sirolimus-Eluting Stent Implantation: Comparison With Bare-Metal Stents Circulation, August 21, 2007; 116(8): 910 - 916. [Abstract] [Full Text] [PDF]

				E. Camenzind, P. G. Steg, and W. Wijns A Cause for Concern Circulation, March 20, 2007; 115(11): 1440 - 1455. [Full Text] [PDF]

				R. M. Wolfram, A. C. Budinsky, B. Pokrajac, R. Potter, and E. Minar Endovascular Brachytherapy for Prophylaxis of Restenosis after Femoropopliteal Angioplasty: Five-year Follow-up--Prospective Randomized Study Radiology, September 1, 2006; 240(3): 878 - 884. [Abstract] [Full Text] [PDF]

				F. Alfonso, M.-J. Perez-Vizcayno, R. Hernandez, A. Bethencourt, V. Marti, J. R. Lopez-Minguez, J. Angel, R. Mantilla, C. Moris, A. Cequier, et al. A Randomized Comparison of Sirolimus-Eluting Stent With Balloon Angioplasty in Patients With In-Stent Restenosis: Results of the Restenosis Intrastent: Balloon Angioplasty Versus Elective Sirolimus-Eluting Stenting (RIBS-II) Trial J. Am. Coll. Cardiol., June 6, 2006; 47(11): 2152 - 2160. [Abstract] [Full Text] [PDF]

				H. L. Dauerman Treatment of Stent Restenosis: Moving Beyond Momentum J. Am. Coll. Cardiol., June 6, 2006; 47(11): 2161 - 2163. [Full Text] [PDF]

				G. Weisz, M. B. Leon, D. R. Holmes Jr, D. J. Kereiakes, M. R. Clark, B. M. Cohen, S. G. Ellis, P. Coleman, C. Hill, C. Shi, et al. Two-Year Outcomes After Sirolimus-Eluting Stent Implantation: Results From the Sirolimus-Eluting Stent in de Novo Native Coronary Lesions (SIRIUS) Trial J. Am. Coll. Cardiol., April 4, 2006; 47(7): 1350 - 1355. [Abstract] [Full Text] [PDF]

				D. R. Holmes Jr, P. Teirstein, L. Satler, M. Sketch, J. O'Malley, J. J. Popma, R. E. Kuntz, P. J. Fitzgerald, H. Wang, E. Caramanica, et al. Sirolimus-Eluting Stents vs Vascular Brachytherapy for In-Stent Restenosis Within Bare-Metal Stents: The SISR Randomized Trial JAMA, March 15, 2006; 295(11): 1264 - 1273. [Abstract] [Full Text] [PDF]

				D. Mukherjee and D. J. Moliterno Brachytherapy for In-Stent Restenosis: A Distant Second Choice to Drug-Eluting Stent Placement JAMA, March 15, 2006; 295(11): 1307 - 1309. [Full Text] [PDF]

				J. Aoki, A. Colombo, D. Dudek, A. P. Banning, J. Drzewiecki, K. Zmudka, F. Schiele, M. E. Russell, J. Koglin, P. W. Serruys, et al. Peristent Remodeling and Neointimal Suppression 2 Years After Polymer-Based, Paclitaxel-Eluting Stent Implantation: Insights From Serial Intravascular Ultrasound Analysis in the TAXUS II Study Circulation, December 20, 2005; 112(25): 3876 - 3883. [Abstract] [Full Text] [PDF]

				F. Alfonso, J. M. Auge, J. Zueco, A. Bethencourt, J. R. Lopez-Minguez, J. M. Hernandez, J. A. Bullones, I. Calvo, E. Esplugas, M. J. Perez-Vizcayno, et al. Long-Term Results (Three to Five Years) of the Restenosis Intrastent: Balloon Angioplasty Versus Elective Stenting (RIBS) Randomized Study J. Am. Coll. Cardiol., September 6, 2005; 46(5): 756 - 760. [Abstract] [Full Text] [PDF]

				A. Kastrati, J. Mehilli, N. von Beckerath, A. Dibra, J. Hausleiter, J. Pache, H. Schuhlen, C. Schmitt, J. Dirschinger, A. Schomig, et al. Sirolimus-Eluting Stent or Paclitaxel-Eluting Stent vs Balloon Angioplasty for Prevention of Recurrences in Patients With Coronary In-Stent Restenosis: A Randomized Controlled Trial JAMA, January 12, 2005; 293(2): 165 - 171. [Abstract] [Full Text] [PDF]

				J. Hausleiter, A. Kastrati, J. Mehilli, M. Vogeser, D. Zohlnhofer, H. Schuhlen, C. Goos, J. Pache, F. Dotzer, G. Pogatsa-Murray, et al. Randomized, Double-Blind, Placebo-Controlled Trial of Oral Sirolimus for Restenosis Prevention in Patients With In-Stent Restenosis: The Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) Trial Circulation, August 17, 2004; 110(7): 790 - 795. [Abstract] [Full Text] [PDF]

				P. S. Teirstein A Chicken in Every Pot and a Drug-Eluting Stent in Every Lesion Circulation, April 27, 2004; 109(16): 1906 - 1910. [Full Text] [PDF]

				R. SoRelle Cardiovascular News Circulation, January 27, 2004; 109 (3): e9004 - e9005. [Full Text]